Viking Therapeutics, Inc. (VKTX) analyst actions
Rating and price-target actions on VKTX in the public-source dataset. Wires and filings carry few rating actions, so this list is sparse by nature — the hub's by-event-type table holds the measured analyst base rates. Back to the VKTX overview →
6 measured VKTX analyst action events.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| Viking Therapeutics Announces Initiation of VK2735 Oral Phase 3 Clinical Program in Patients with Obesity | Press release | -0.68% | -3.89% | |
| Viking Therapeutics Announces Initiation of VK2735 Oral Maintenance Dosing Clinical Trial in Patients with Obesity | Press release | -0.83% | -3.76% | |
| Viking Therapeutics Announces Initiation of Phase 1 Study to Evaluate Novel Amylin Receptor Agonist VK3019 in Healthy Adults | Press release | +0.06% | +6.29% | |
| Viking Therapeutics Announces Initiation of VK2735 Maintenance Dosing Clinical Trial in Patients with Obesity | Press release | -0.19% | -2.37% | |
| Viking Therapeutics Announces Initiation of Phase 3 Obesity Clinical Program with GLP-1/GIP Agonist VK2735 | Press release | -1.49% | -0.07% | |
| Viking Therapeutics Announces Initiation of Phase 2 VENTURE-Oral Dosing Trial of VK2735 Tablet Formulation in Patients with Obesity | Press release | -1.30% | -2.22% |
Keep exploring
More VKTX: earnings → · SEC filings → · VKTX overview →
Other Healthcare names and their analyst actions
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| Pulse Biosciences, Inc (PLSE) | 320 | +0.18% | 55% |
| Voyager Therapeutics, Inc. (VYGR) | 320 | -0.12% | 42% |
| Aptevo Therapeutics Inc. (APVO) | 318 | -0.89% | 34% |
| MATEON THERAPEUTICS (MATN) | 318 | 0.00% | 35% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not. These are each name’s all-news baseline, not its analyst actions — that is what the link opens.